Preliminary data for omega-3 fatty acid supplements (Eyetas) also indicate potential with 6 ETDRS letter improvement in BCVA for treated STGD1 and AMD patients compared to the placebo at 6 months [81]. Here, ABCA4 is linked to age-related macular degeneration.